Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 135


Ultramarathon Plasma Metabolomics: Phosphatidylcholine Levels Associated with Running Performance.

Høeg TB, Chmiel K, Warrick AE, Taylor SL, Weiss RH.

Sports (Basel). 2020 Apr 1;8(4). pii: E44. doi: 10.3390/sports8040044.


A high-throughput screening platform for Polycystic Kidney Disease (PKD) drug repurposing utilizing murine and human ADPKD cells.

Asawa RR, Danchik C, Zahkarov A, Chen Y, Voss T, Jadhav A, Wallace DP, Trott JF, Weiss RH, Simeonov A, Martinez NJ.

Sci Rep. 2020 Mar 6;10(1):4203. doi: 10.1038/s41598-020-61082-3.


Introduction: Why Do We Need a Special Volume on Kidney Cancer?

Weiss RH.

Semin Nephrol. 2020 Jan;40(1):1. doi: 10.1016/j.semnephrol.2019.12.001. No abstract available.


The Cell-Cycle Regulatory Protein p21CIP1/WAF1 Is Required for Cytolethal Distending Toxin (Cdt)-Induced Apoptosis.

Shenker BJ, Walker LM, Zekavat A, Weiss RH, Boesze-Battaglia K.

Pathogens. 2020 Jan 2;9(1). pii: E38. doi: 10.3390/pathogens9010038.


Targeting the vasopressin type-2 receptor for renal cell carcinoma therapy.

Sinha S, Dwivedi N, Tao S, Jamadar A, Kakade VR, Neil MO, Weiss RH, Enders J, Calvet JP, Thomas SM, Rao R.

Oncogene. 2020 Feb;39(6):1231-1245. doi: 10.1038/s41388-019-1059-0. Epub 2019 Oct 15.


Plasma metabolites and lipids associate with kidney function and kidney volume in hypertensive ADPKD patients early in the disease course.

Kim K, Trott JF, Gao G, Chapman A, Weiss RH.

BMC Nephrol. 2019 Feb 25;20(1):66. doi: 10.1186/s12882-019-1249-6.


Translating L-2-HG to kidney cancer at the bench and bedside.

Aboud OA, Weiss RH.

Ann Transl Med. 2018 Dec;6(Suppl 2):S103. doi: 10.21037/atm.2018.11.41. No abstract available.


Targeting the insulin-like growth factor-1 receptor in MTAP-deficient renal cell carcinoma.

Xu J, Chang WH, Fong LWR, Weiss RH, Yu SL, Chen CH.

Signal Transduct Target Ther. 2019 Jan 25;4:2. doi: 10.1038/s41392-019-0035-z. eCollection 2019.


XPO1 inhibition by selinexor induces potent cytotoxicity against high grade bladder malignancies.

Baek HB, Lombard AP, Libertini SJ, Fernandez-Rubio A, Vinall R, Gandour-Edwards R, Nakagawa R, Vidallo K, Nishida K, Siddiqui S, Wettersten H, Landesman Y, Weiss RH, Ghosh PM, Mudryj M.

Oncotarget. 2018 Oct 2;9(77):34567-34581. doi: 10.18632/oncotarget.26179. eCollection 2018 Oct 2.


Translating Metabolic Reprogramming into New Targets for Kidney Cancer.

Abu Aboud O, Weiss RH.

Kidney Cancer. 2017 Nov 27;1(2):93-97. doi: 10.3233/KCA-170014.


Arginine reprogramming in ADPKD results in arginine-dependent cystogenesis.

Trott JF, Hwang VJ, Ishimaru T, Chmiel KJ, Zhou JX, Shim K, Stewart BJ, Mahjoub MR, Jen KY, Barupal DK, Li X, Weiss RH.

Am J Physiol Renal Physiol. 2018 Dec 1;315(6):F1855-F1868. doi: 10.1152/ajprenal.00025.2018. Epub 2018 Oct 3.


Management of the Incidental Kidney Mass in the Nephrology Clinic.

Hu SL, Weiss RH.

Clin J Am Soc Nephrol. 2018 Sep 7;13(9):1407-1409. doi: 10.2215/CJN.00860118. Epub 2018 Apr 13. No abstract available.


Metabolomics and Metabolic Reprogramming in Kidney Cancer.

Weiss RH.

Semin Nephrol. 2018 Mar;38(2):175-182. doi: 10.1016/j.semnephrol.2018.01.006. Review.


The role of nephrologists in the management of small renal masses.

Hu SL, Weiss RH.

Nat Rev Nephrol. 2018 Apr;14(4):211-212. doi: 10.1038/nrneph.2018.10. Epub 2018 Feb 5. No abstract available.


The glucose and lipid metabolism reprogramming is grade-dependent in clear cell renal cell carcinoma primary cultures and is targetable to modulate cell viability and proliferation.

Bianchi C, Meregalli C, Bombelli S, Di Stefano V, Salerno F, Torsello B, De Marco S, Bovo G, Cifola I, Mangano E, Battaglia C, Strada G, Lucarelli G, Weiss RH, Perego RA.

Oncotarget. 2017 Dec 8;8(69):113502-113515. doi: 10.18632/oncotarget.23056. eCollection 2017 Dec 26.


Rho GTPase effectors and NAD metabolism in cancer immune suppression.

Chaker M, Minden A, Chen S, Weiss RH, Chini EN, Mahipal A, Azmi AS.

Expert Opin Ther Targets. 2018 Jan;22(1):9-17. doi: 10.1080/14728222.2018.1413091. Epub 2017 Dec 10. Review.


The Presented Evidence to Support Symptomatic Hypovolemic-Associated EAH Is Not Convincing.

Hoffman MD, Weiss RH.

Curr Sports Med Rep. 2017 Nov/Dec;16(6):464-466. doi: 10.1249/JSR.0000000000000420. No abstract available.


Glutamine Addiction in Kidney Cancer Suppresses Oxidative Stress and Can Be Exploited for Real-Time Imaging.

Abu Aboud O, Habib SL, Trott J, Stewart B, Liang S, Chaudhari AJ, Sutcliffe J, Weiss RH.

Cancer Res. 2017 Dec 1;77(23):6746-6758. doi: 10.1158/0008-5472.CAN-17-0930. Epub 2017 Oct 11.


Anticystogenic activity of a small molecule PAK4 inhibitor may be a novel treatment for autosomal dominant polycystic kidney disease.

Hwang VJ, Zhou X, Chen X, Trott J, Abu Aboud O, Shim K, Dionne LK, Chmiel KJ, Senapedis W, Baloglu E, Mahjoub MR, Li X, Weiss RH.

Kidney Int. 2017 Oct;92(4):922-933. doi: 10.1016/j.kint.2017.03.031. Epub 2017 May 23.


Metabolic reprogramming in clear cell renal cell carcinoma.

Wettersten HI, Aboud OA, Lara PN Jr, Weiss RH.

Nat Rev Nephrol. 2017 Jul;13(7):410-419. doi: 10.1038/nrneph.2017.59. Epub 2017 May 8. Review.


GHetting to know ADPKD proliferative signaling, STAT.

Chen CH, Weiss RH.

Kidney Int. 2017 Mar;91(3):524-526. doi: 10.1016/j.kint.2016.11.024.


Upregulation of MARCKS in kidney cancer and its potential as a therapeutic target.

Chen CH, Fong LWR, Yu E, Wu R, Trott JF, Weiss RH.

Oncogene. 2017 Jun 22;36(25):3588-3598. doi: 10.1038/onc.2016.510. Epub 2017 Feb 6.


Metabolomic profiling for early cancer detection: current status and future prospects.

Hwang VJ, Weiss RH.

Expert Opin Drug Metab Toxicol. 2016 Nov;12(11):1263-1265. doi: 10.1080/17425255.2016.1238460. Epub 2016 Sep 23. No abstract available.


Multivariate two-part statistics for analysis of correlated mass spectrometry data from multiple biological specimens.

Taylor SL, Ruhaak LR, Weiss RH, Kelly K, Kim K.

Bioinformatics. 2017 Jan 1;33(1):17-25. doi: 10.1093/bioinformatics/btw578. Epub 2016 Sep 4.


Inhibiting tryptophan metabolism enhances interferon therapy in kidney cancer.

Trott JF, Kim J, Abu Aboud O, Wettersten H, Stewart B, Berryhill G, Uzal F, Hovey RC, Chen CH, Anderson K, Graef A, Sarver AL, Modiano JF, Weiss RH.

Oncotarget. 2016 Oct 11;7(41):66540-66557. doi: 10.18632/oncotarget.11658.


Dual and Specific Inhibition of NAMPT and PAK4 By KPT-9274 Decreases Kidney Cancer Growth.

Abu Aboud O, Chen CH, Senapedis W, Baloglu E, Argueta C, Weiss RH.

Mol Cancer Ther. 2016 Sep;15(9):2119-29. doi: 10.1158/1535-7163.MCT-16-0197. Epub 2016 Jul 7.


The Nephrologist's Tumor: Basic Biology and Management of Renal Cell Carcinoma.

Hu SL, Chang A, Perazella MA, Okusa MD, Jaimes EA, Weiss RH; American Society of Nephrology Onco-Nephrology Forum.

J Am Soc Nephrol. 2016 Aug;27(8):2227-37. doi: 10.1681/ASN.2015121335. Epub 2016 Mar 9. Review.


Addition of DHA Synergistically Enhances the Efficacy of Regorafenib for Kidney Cancer Therapy.

Kim J, Ulu A, Wan D, Yang J, Hammock BD, Weiss RH.

Mol Cancer Ther. 2016 May;15(5):890-8. doi: 10.1158/1535-7163.MCT-15-0847. Epub 2016 Feb 26.


Effects of imputation on correlation: implications for analysis of mass spectrometry data from multiple biological matrices.

Taylor SL, Ruhaak LR, Kelly K, Weiss RH, Kim K.

Brief Bioinform. 2017 Mar 1;18(2):312-320. doi: 10.1093/bib/bbw010.


Cancers Best Paper Award 2015.

Weiss RH.

Cancers (Basel). 2015 May 29;7(2):963-5. doi: 10.3390/cancers7020818.


Changes in PTGS1 and ALOX12 Gene Expression in Peripheral Blood Mononuclear Cells Are Associated with Changes in Arachidonic Acid, Oxylipins, and Oxylipin/Fatty Acid Ratios in Response to Omega-3 Fatty Acid Supplementation.

Berthelot CC, Kamita SG, Sacchi R, Yang J, Nording ML, Georgi K, Hegedus Karbowski C, German JB, Weiss RH, Hogg RJ, Hammock BD, Zivkovic AM.

PLoS One. 2015 Dec 16;10(12):e0144996. doi: 10.1371/journal.pone.0144996. eCollection 2015.


Does Acute Kidney Injury From an Ultramarathon Increase the Risk for Greater Subsequent Injury?

Hoffman MD, Weiss RH.

Clin J Sport Med. 2016 Sep;26(5):417-22. doi: 10.1097/JSM.0000000000000277.


Atorvastatin restricts HIV replication in CD4+ T cells by upregulation of p21.

Elahi S, Weiss RH, Merani S.

AIDS. 2016 Jan;30(2):171-83. doi: 10.1097/QAD.0000000000000917.


The cpk model of recessive PKD shows glutamine dependence associated with the production of the oncometabolite 2-hydroxyglutarate.

Hwang VJ, Kim J, Rand A, Yang C, Sturdivant S, Hammock B, Bell PD, Guay-Woodford LM, Weiss RH.

Am J Physiol Renal Physiol. 2015 Sep 15;309(6):F492-8. doi: 10.1152/ajprenal.00238.2015. Epub 2015 Jul 8.


Spontaneous γH2AX Foci in Human Solid Tumor-Derived Cell Lines in Relation to p21WAF1 and WIP1 Expression.

Mirzayans R, Andrais B, Scott A, Wang YW, Weiss RH, Murray D.

Int J Mol Sci. 2015 May 20;16(5):11609-28. doi: 10.3390/ijms160511609.


Grade-Dependent Metabolic Reprogramming in Kidney Cancer Revealed by Combined Proteomics and Metabolomics Analysis.

Wettersten HI, Hakimi AA, Morin D, Bianchi C, Johnstone ME, Donohoe DR, Trott JF, Aboud OA, Stirdivant S, Neri B, Wolfert R, Stewart B, Perego R, Hsieh JJ, Weiss RH.

Cancer Res. 2015 Jun 15;75(12):2541-52. doi: 10.1158/0008-5472.CAN-14-1703. Epub 2015 May 7.


PPARα inhibition modulates multiple reprogrammed metabolic pathways in kidney cancer and attenuates tumor growth.

Abu Aboud O, Donohoe D, Bultman S, Fitch M, Riiff T, Hellerstein M, Weiss RH.

Am J Physiol Cell Physiol. 2015 Jun 1;308(11):C890-8. doi: 10.1152/ajpcell.00322.2014. Epub 2015 Mar 25.


On-chip detection of a single nucleotide polymorphism without polymerase amplification.

Han J, Tan M, Sudheendra L, Weiss RH, Kennedy IM.

Nano Res. 2014 Sep 1;7(9):1302-1310.


Biomarkers in IgA nephropathy.

Hwang VJ, Ulu A, van Hoorebeke J, Weiss RH.

Biomark Med. 2014;8(10):1263-77. doi: 10.2217/bmm.14.92. Review.


Specific inhibition of the nuclear exporter exportin-1 attenuates kidney cancer growth.

Wettersten HI, Landesman Y, Friedlander S, Shacham S, Kauffman M, Weiss RH.

PLoS One. 2014 Dec 2;9(12):e113867. doi: 10.1371/journal.pone.0113867. eCollection 2014.


Biological evaluation of a novel sorafenib analogue, t-CUPM.

Wecksler AT, Hwang SH, Liu JY, Wettersten HI, Morisseau C, Wu J, Weiss RH, Hammock BD.

Cancer Chemother Pharmacol. 2015 Jan;75(1):161-71. doi: 10.1007/s00280-014-2626-2. Epub 2014 Nov 21.


Novel inhibitors of nuclear transport cause cell cycle arrest and decrease cyst growth in ADPKD associated with decreased CDK4 levels.

Tan M, Wettersten HI, Chu K, Huso DL, Watnick T, Friedlander S, Landesman Y, Weiss RH.

Am J Physiol Renal Physiol. 2014 Dec 1;307(11):F1179-86. doi: 10.1152/ajprenal.00406.2014. Epub 2014 Sep 18.


Dual inhibition of cyclooxygenase-2 and soluble epoxide hydrolase synergistically suppresses primary tumor growth and metastasis.

Zhang G, Panigrahy D, Hwang SH, Yang J, Mahakian LM, Wettersten HI, Liu JY, Wang Y, Ingham ES, Tam S, Kieran MW, Weiss RH, Ferrara KW, Hammock BD.

Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):11127-32. doi: 10.1073/pnas.1410432111. Epub 2014 Jul 14.


Synergistic tumor suppression by combined inhibition of telomerase and CDKN1A.

Gupta R, Dong Y, Solomon PD, Wettersten HI, Cheng CJ, Min JN, Henson J, Dogra SK, Hwang SH, Hammock BD, Zhu LJ, Reddel RR, Saltzman WM, Weiss RH, Chang S, Green MR, Wajapeyee N.

Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):E3062-71. doi: 10.1073/pnas.1411370111. Epub 2014 Jul 14.


Exercise-associated hyponatremia with exertional rhabdomyolysis: importance of proper treatment.

Hoffman MD, Stuempfle KJ, Sullivan K, Weiss RH.

Clin Nephrol. 2015 Apr;83(4):235-42. doi: 10.5414/CN108233.


Metabolomic profiling of tumor-bearing mice.

Wettersten HI, Ganti S, Weiss RH.

Methods Enzymol. 2014;543:275-96. doi: 10.1016/B978-0-12-801329-8.00014-3.


Symptomatic hypotonic hyponatremia presenting at high altitude.

Hoffman MD, Weiss RH.

Wilderness Environ Med. 2014 Sep;25(3):362-3. doi: 10.1016/j.wem.2014.01.008. Epub 2014 Apr 24. No abstract available.


Novel sorafenib-based structural analogues: in-vitro anticancer evaluation of t-MTUCB and t-AUCMB.

Wecksler AT, Hwang SH, Wettersten HI, Gilda JE, Patton A, Leon LJ, Carraway KL 3rd, Gomes AV, Baar K, Weiss RH, Hammock BD.

Anticancer Drugs. 2014 Apr;25(4):433-46. doi: 10.1097/CAD.0000000000000079.

Supplemental Content

Loading ...
Support Center